Cargando…
An alternative method to analyse the biomarker‐strategy design
Recent developments in genomics and proteomics enable the discovery of biomarkers that allow identification of subgroups of patients responding well to a treatment. One currently used clinical trial design incorporating a predictive biomarker is the so‐called biomarker strategy design (or marker‐bas...
Autores principales: | Kunz, Cornelia Ursula, Jaki, Thomas, Stallard, Nigel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492198/ https://www.ncbi.nlm.nih.gov/pubmed/30260533 http://dx.doi.org/10.1002/sim.7940 |
Ejemplares similares
-
A Comparison of Methods for Treatment Selection in Seamless Phase II/III Clinical Trials Incorporating Information on Short-Term Endpoints
por: Kunz, Cornelia Ursula, et al.
Publicado: (2015) -
An adaptive biomarker strategy clinical trial design
por: Wason, James, et al.
Publicado: (2013) -
Should the two‐trial paradigm still be the gold standard in drug assessment?
por: Zhan, Stella Jinran, et al.
Publicado: (2022) -
Flexible selection of a single treatment incorporating short‐term endpoint information in a phase II/III clinical trial
por: Stallard, Nigel, et al.
Publicado: (2015) -
Planning multi-arm screening studies within the context of a drug development program
por: Wason, James M S, et al.
Publicado: (2013)